Epstein-Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV.

Change log

Chronic active Epstein-Barr virus (CAEBV) disease is a rare condition characterised by persistent EBV infection in previously healthy individuals. Defective EBV genomes were found in East Asian patients with CAEBV. In the present study, we sequenced 14 blood EBV samples from three UK patients with CAEBV, comparing the results with saliva CAEBV samples and other conditions. We observed EBV deletions in blood, some of which may disrupt viral replication, but not saliva in CAEBV. Deletions were lost overtime after successful treatment. These findings are compatible with CAEBV being associated with the evolution and persistence of EBV+ haematological clones that are lost on successful treatment.


Funder: NIHR Imperial Biomedical Research Centre; Id: http://dx.doi.org/10.13039/501100013342

Funder: NIHR UCL

Funder: UCLH BRC

Funder: National Institute of Allergy and Infectious Diseases; Id: http://dx.doi.org/10.13039/100000060

Epstein-Barr virus, chronic active EBV, defective viral genome, Adolescent, Biomarkers, Case-Control Studies, Child, Child, Preschool, Chronic Disease, Defective Viruses, Epstein-Barr Virus Infections, Asia, Eastern, Female, Herpesvirus 4, Human, Humans, Immunologic Factors, Male, Peripheral Blood Stem Cell Transplantation, Polymorphism, Single Nucleotide, Rituximab, Saliva, Sequence Deletion, Treatment Outcome, Virus Replication
Is Part Of
Wellcome Trust (204870/Z/16/Z, 206478/Z/17/Z)
MRC (MR/S022597/1)